Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Boland

Showing results (551-560 of 571) with videos related to

Pageof 58
Sort By:
Science Advances|November 27, 2024
Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanomaGiuseppe Tarantino, Cora A Ricker, Annette Wang, et al.
Eclinicalmedicine|April 4, 2024
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in <i>BRAF</i> V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyXue Bai, Ahmed Shaheen, Charlotte Grieco, et al.
Eclinicalmedicine|November 15, 2023
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in <i>BRAF</i> V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyXue Bai, Ahmed Shaheen, Charlotte Grieco, et al.
Biorxiv : the Preprint Server for Biology|December 16, 2024
Potent antitumor activity of a designed interleukin-21 mimicJung-Ho Chun, Birkley S Lim, Suyasha Roy, et al.
Science Immunology|September 26, 2025
Design of a potent interleukin-21 mimic for cancer immunotherapyJung-Ho Chun, Birkley S Lim, Suyasha Roy, et al.
Cell Reports. Medicine|March 4, 2022
Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanomaSamuel S Freeman, Moshe Sade-Feldman, Jaegil Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2021
Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal CancerAparna R Parikh, Emily E Van Seventer, Giulia Siravegna, et al.
Cancer Research|August 31, 2021
Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy ResistanceJianglan Liu, Vito W Rebecca, Andrew V Kossenkov, et al.
Annals of Surgical Oncology|April 15, 2022
Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)Alexander C J van Akkooi, Tina J Hieken, Elizabeth M Burton, et al.
Annals of Surgical Oncology|January 28, 2022
Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)Alexander C J van Akkooi, Tina J Hieken, Elizabeth M Burton, et al.
Pageof 58

Showing results (551-560 of 571) with videos related to

Sort By:
Pageof 58
Science Advances|November 27, 2024
Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanomaGiuseppe Tarantino, Cora A Ricker, Annette Wang, et al.
Eclinicalmedicine|April 4, 2024
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in <i>BRAF</i> V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyXue Bai, Ahmed Shaheen, Charlotte Grieco, et al.
Eclinicalmedicine|November 15, 2023
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in <i>BRAF</i> V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyXue Bai, Ahmed Shaheen, Charlotte Grieco, et al.
Biorxiv : the Preprint Server for Biology|December 16, 2024
Potent antitumor activity of a designed interleukin-21 mimicJung-Ho Chun, Birkley S Lim, Suyasha Roy, et al.
Science Immunology|September 26, 2025
Design of a potent interleukin-21 mimic for cancer immunotherapyJung-Ho Chun, Birkley S Lim, Suyasha Roy, et al.
Cell Reports. Medicine|March 4, 2022
Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanomaSamuel S Freeman, Moshe Sade-Feldman, Jaegil Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2021
Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal CancerAparna R Parikh, Emily E Van Seventer, Giulia Siravegna, et al.
Cancer Research|August 31, 2021
Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy ResistanceJianglan Liu, Vito W Rebecca, Andrew V Kossenkov, et al.
Annals of Surgical Oncology|April 15, 2022
Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)Alexander C J van Akkooi, Tina J Hieken, Elizabeth M Burton, et al.
Annals of Surgical Oncology|January 28, 2022
Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)Alexander C J van Akkooi, Tina J Hieken, Elizabeth M Burton, et al.
Pageof 58